Zogenix (ZGNX) Misses Q4 EPS by 3c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/2/2026

1. AMZN
2. INTC
3. RDDT
4. COIN
5. PINS
6. FSLR
7. SYK
8. DASH
9. GILD
10. SBUX

Go back to Zogenix (ZGNX) Misses Q4 EPS by 3c

Zogenix Reports Fourth Quarter and Full Year 2014 Financial Results

March 10, 2015 4:05 PM EDT

Clinical and Regulatory Update

Received FDA approval for new formulation of Zohydro® ER (hydrocodone bitartrate) Extended-Release Capsules, CII, with BeadTek On track to begin Phase 3 clinical study for ZX008 (orphan drug candidate for Dravet syndrome) in the third quarter 2015; data expected in 2016 Enrolled first patient in Relday (novel long-acting injectable formulation of risperidone for schizophrenia) multi-dose clinical study; data on track for third quarter 2015

Fourth Quarter 2014 Highlights

Total prescriptions for Zohydro ER were 18,956, up 25% compared to the third quarter1 Total net revenue of $14.9 million Net... More